(Reuters) - Repros Therapeutics Inc will abandon efforts to seek approval for its testosterone drug in the United States if an ongoing study fails, and shift focus to its uterine fibroids drug that showed promise in a mid-stage trial.
http://ift.tt/xePdMM
from Reuters: Health News
via animenewspro
Aucun commentaire:
Enregistrer un commentaire